• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Maravai LifeSciences Holdings (MRVI) Stock Dropped, So What Is Behind The Move?

    Simply Wall St·10/14/2026 21:27:08
    語音播報

    Maravai LifeSciences Q2 Event Sets The Stage

    Maravai LifeSciences Holdings (MRVI) recently reported Q2 2026 revenue of US$51.4 million, with TriLink and Cygnus each contributing to year over year growth, a wider adjusted gross margin, and stronger adjusted EBITDA.

    Maravai LifeSciences shares have pulled back sharply in the short term, with the 1 day share price return down 7.5% and the 7 day share price return down 16.8%. However, the year to date share price return sits at 92.1% and the 1 year total shareholder return is 102.2%, which highlights strong longer term momentum even after the recent drop.

    Scan beyond Maravai LifeSciences and compare this kind of margin and refinancing story with a curated set of 32 high quality undervalued stocks that combine resilient balance sheets with cash flow strength.

    After a 92.1% year to date climb followed by a sharp pullback, Maravai LifeSciences now forces a choice. Does it make more sense to step in here, or wait for a cheaper reset as valuation work unfolds next?

    Most Popular Narrative: 14% Undervalued

    Maravai LifeSciences trades at $6.53 against a widely followed fair value estimate of $7.60, which frames the recent pullback as a valuation reset rather than a complete break in the story.

    The company's restructuring plan, including streamlining operations, consolidating executive roles, and targeting over $50 million in annualized cost savings, is expected to significantly lower SG&A expenses, restore EBITDA margins, and support a return to positive free cash flow by the second half of 2026, directly improving earnings.

    See why 2 investors see Maravai LifeSciences Holdings as 14% undervalued.

    Result: Fair Value of $7.60 (UNDERVALUED)

    Still, the narrative around Maravai LifeSciences could be knocked off course if revenue lumpiness persists or if heavy reliance on key CleanCap products weighs on visibility.

    Find out about the key risks to this Maravai LifeSciences Holdings narrative.

    Another View: What Multiples Say About Maravai LifeSciences

    The earlier SWS DCF work points to Maravai LifeSciences at $6.53 trading below an estimated future cash flow value of $15.22, which leans clearly undervalued. The P/S ratio tells a cooler story. At 4.7x revenue, the stock sits slightly above the US Life Sciences industry on 4.5x and above a fair ratio of 3x. That gap suggests the market already prices in a fair amount of optimism. The question is whether the cash flow case or the sales multiple ends up being closer to reality for you.

    To stress test that view using numbers rather than headlines, take a closer look at how this price stacks up in our valuation breakdown, including the fair ratio and peer comparisons, through See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:MRVI P/S Ratio as at Oct 2026
    NasdaqGS:MRVI P/S Ratio as at Oct 2026

    Next Steps

    Mixed signals around Maravai LifeSciences can feel noisy, so move quickly, study the underlying data, and decide what really matters to you with 1 key reward and 1 important warning sign

    Looking For More Investment Ideas Beyond Maravai LifeSciences?

    If Maravai LifeSciences has sharpened your focus, do not stop here. Use the Simply Wall St screener to line up your next set of potential opportunities.

    • Spot potential value plays before they move by scanning our 32 high quality undervalued stocks with strong fundamentals and room for a better price to story trade off.
    • Lock in income ideas by reviewing a curated set of 8 dividend fortresses that combine meaningful yields with balance sheets that help support ongoing payouts.
    • Get ahead of the crowd by filtering for 20 high quality undiscovered gems that pair solid financials with limited market attention so far.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.